alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 74, Number 119 (Tuesday, June 23, 2009)]
[Notices]
[Page 29735]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-14656]


=======================================================================
-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION


Sunshine Act Meeting

Federal Register Citation of Previous Announcement: [to be published]

Status: Closed Meeting.

Place: 100 F Street, NW., Washington, DC.

Date and Time of Previously Announced Meeting: June 19, 2009 at 11 a.m.

Change In the Meeting: Deletion of an Item.
    The following item will not be considered during the Closed Meeting 
on Friday, June 19, 2009: Formal order of investigation.
    At times, changes in Commission priorities require alterations in 
the scheduling of meeting items. For further information and to 
ascertain what, if any, matters have been added, deleted or postponed, 
please contact the Office of the Secretary at (202) 551-5400.

    Dated: June 17, 2009.
Elizabeth M. Murphy,
Secretary.
[FR Doc. E9-14656 Filed 6-22-09; 8:45 am]
BILLING CODE 8010-01-P
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Justice

###### Drug Enforcement Administration

                    Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 22, 2009, Noramco Inc., Division of Ortho-McNeil, Inc., 1440 Olympic Drive, Athens, GA 30601, made application by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of Tapentadol                           ( print page 29720)                        (9780), a basic class of controlled substance listed in schedule II.                

The company plans to bulk manufacture the above listed controlled substance for distribution to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, VA 22152; and must be filed no later than August 24, 2009.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E9-14705 Filed 6-22-09; 8:45 am]

BILLING CODE 4410-09-P
EXHIBIT
      32.2




CERTIFICATION
      PURSUANT TO


18
      U.S.C.
      SECTION 1350,


AS
      ADOPTED PURSUANT TO


SECTION
      906 OF THE SARBANES-OXLEY ACT OF 2002





In
      connection with the quarterly report of Web2 Corp. (the “Company”) on Form
      10-QSB for the quarter ending September 30, 2007 as filed with the Securities
      and Exchange Commission on December 20, 2007 (the “Report”), I, William A.
      Mobley, Jr., Chief Financial Officer of the Company, certify, pursuant to 18
      U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of
      2002, that:





(1)
            The
                Report fully complies with the requirements of section 13(a) or 15(d)
                of
                the Securities Exchange Act of 1934;
                and





(2)
            The
                information contained in the Report fairly presents, in all material
                respects, the financial condition and result of operations of the
                Company.







/s/
      William A. Mobley, Jr.





William
      A. Mobley, Jr.


Chief
      Financial Officer


December
      20, 2007
[Federal Register Volume 74, Number 120 (Wednesday, June 24, 2009)]
[Notices]
[Page 30069]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-14786]


-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER09-1283-000]


The Energy Cooperative of Pennsylvania, Inc.; Supplemental Notice 
That Initial Market-Based Rate Filing Includes Request for Blanket 
Section 204 Authorization

June 17, 2009.
    This is a supplemental notice in the above-referenced proceeding of 
The Energy Cooperative of Pennsylvania, Inc.'s application for market-
based rate authority, with an accompanying rate tariff, noting that 
such application includes a request for blanket authorization, under 18 
CFR Part 34, of future issuances of securities and assumptions of 
liability.
    Any person desiring to intervene or to protest should file with the 
Federal Energy Regulatory Commission, 888 First Street, NE., 
Washington, DC 20426, in accordance with Rules 211 and 214 of the 
Commission's Rules of Practice and Procedure (18 CFR 385.211 and 
385.214). Anyone filing a motion to intervene or protest must serve a 
copy of that document on the Applicant.
    Notice is hereby given that the deadline for filing protests with 
regard to the applicant's request for blanket authorization, under 18 
CFR Part 34, of future issuances of securities and assumptions of 
liability, is July 16, 2009.
    The Commission encourages electronic submission of protests and 
interventions in lieu of paper, using the FERC Online links at http://www.ferc.gov. To facilitate electronic service, persons with Internet 
access who will eFile a document and/or be listed as a contact for an 
intervenor must create and validate an eRegistration account using the 
eRegistration link. Select the eFiling link to log on and submit the 
intervention or protests.
    Persons unable to file electronically should submit an original and 
14 copies of the intervention or protest to the Federal Energy 
Regulatory Commission, 888 First St., NE., Washington, DC 20426.
    The filings in the above-referenced proceeding are accessible in 
the Commission's eLibrary system by clicking on the appropriate link in 
the above list.
    They are also available for review in the Commission's Public 
Reference Room in Washington, DC. There is an eSubscription link on the 
Web site that enables subscribers to receive e-mail notification when a 
document is added to a subscribed docket(s). For assistance with any 
FERC Online service, please e-mail <a href="/cdn-cgi/l/email-protection#23656671606c4d4f4a4d46705653534c515763454651400d444c55"><span class="__cf_email__" data-cfemail="89cfccdbcac6e7e5e0e7ecdafcf9f9e6fbfdc9efecfbeaa7eee6ff">[email protected]</span></a>. or call 
(866) 208-3676 (toll free). For TTY, call (202) 502-8659.

Kimberly D. Bose,
 Secretary.
[FR Doc. E9-14786 Filed 6-23-09; 8:45 am]
BILLING CODE 6717-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
```

                                              Consent of Independent Auditors

We consent to the incorporation by reference in this Annual Report (Form 10-K) of Baldor Electric Company and affiliates
of our report dated January 31, 2003 (except for Note B and Note M, as to which the date is March 5, 2003), included in
the 2002 Annual Report to Shareholders of Baldor Electric Company and affiliates.

Our audits also included the financial statement schedule of Baldor Electric Company and affiliates listed in Item 15(a).
This schedule is the responsibility of the Company's management. Our responsibility is to express an opinion based on our
audits. In our opinion, the financial statement schedule referred to above, when considered in relation to the basic
financial statements taken as a whole, presents fairly in all material respects the information set forth therein.

We also consent to the incorporation by reference in the Registration Statements (Form S-8, No. 33-16766) pertaining to
the Baldor Electric Company 1987 Incentive Stock Plan, (Form S-8, No. 33-28239) pertaining to the Baldor Electric Company
Employee Savings Plan, (Form S-8, No. 33-36421) pertaining to the Baldor Electric Company 1989 Stock Option Plan for
Non-Employee Directors, (Forms S-8, No. 33-59281, No. 33-60731, and No. 333-62331) pertaining to the Baldor Electric
Company 1994 Incentive Stock Plan, (Form S-8, No. 333-33109) pertaining to the Baldor Electric Company 1996 Stock Option
Plan for Non-Employee Directors, (Form S-8, No. 333-33287) pertaining to the Baldor Electric Company Employees' Profit
Sharing and Savings Plan, and (Form S-8, No. 333-67474) pertaining to the Stock Option Plan for Non-Employee Directors,
of our report dated January 31, 2003 (except for Note B and Note M, as to which the date is March 5, 2003), with respect
to the consolidated financial statements of Baldor Electric Company and affiliates incorporated by reference and our
report included in the preceding paragraph with respect to the financial statement schedule included in the Annual Report
(Form 10-K) for the year ended December 28, 2002.

                  /s/ Ernst & Young LLP

Little Rock, Arkansas
March 27, 2003
```
#### Marko S., Also Known as Marko Alexander S., Also Known as Marko A., Respondent, v Heather S., Also Known as Heather Kim S., Appellant.

Submitted April 9, 2012;

decided June 5, 2012

Motion for leave to appeal dismissed upon the ground that the order sought to be appealed from does not finally determine the action within the meaning of the Constitution. Motion for poor person relief dismissed as academic.
ACCEPTED

12-14-00196-CR

TWELFTH COURT OF APPEALS

TYLER, TEXAS

7/10/2015 3:27:28 PM

CATHY LUSK

CLERK

 FILED IN 12th COURT OF APPEALS TYLER, TEXAS 7/10/2015 3:27:28 PM CATHY S. LUSK Clerk
MOTION DOCKET

86-1099.

#### State v. Spisak.

Cuyahoga App. Nos. 47458 and 47459. On motion to set execution date. Motion granted.
#### The People of the State of New York, Respondent, v Ingrid Carter Lovitt, Appellant.

[823 NYS2d 116]

Judgment, Supreme Court, New York County (Renee A. White, J.), rendered on or about March 22, 2005, unanimously affirmed. No opinion. Order filed. Concur—Mazzarelli, J.P., Saxe, Marlow, Sullivan and Williams, JJ.
# Canavan Disease

## What is Canavan disease?

Canavan disease is a neurological disorder in which the brain degenerates into spongy tissue full of small fluid-filled spaces. It is caused by a mutation in the ASPA gene which makes an enzyme called aspartoacylase. This enzyme is primarily present in oligodendrocytes, contributes to the manufacture of myelin, and is responsible for breaking down (metabolizing) the brain chemical N-acetyl-L-aspartate or N-acetyl-L-aspartic acid. In Canavan disease, many oligodendrocytes do not mature and instead die, leaving nerve cell projections known as axons vulnerable and unable to properly function.  

Canavan disease causes progressive brain atrophy. There is no cure, nor is there a standard course of treatment. Treatment is symptomatic and supportive. The prognosis for Canavan disease is poor. Death usually occurs before age 10, although some children may survive into their teens and twenties.

file-medical

## How can I or my loved one help improve care for people with Canavan disease?

Consider participating in a clinical trial so clinicians and scientists can learn more about Canavan disease and related conditions. Clinical research uses human volunteers to help researchers learn more about a disorder and perhaps find better ways to safely detect, treat, or prevent disease. 

All types of volunteers are needed—those who are healthy or may have an illness or disease—of all different ages, sexes, races, and ethnicities to ensure that study results apply to as many people as possible, and that treatments will be safe and effective for everyone who will use them. 

For information about participating in clinical research visit NIH Clinical Research Trials and You. Learn about clinical trials currently looking for people with Canavan disease and leukodystrophy at Clinicaltrials.gov, a database of current and past clinical studies and research results. 
> Where can I find more information about Canavan disease?
Information for people living with Canavan disease and their families, friends, and caregivers is available from the following organizations and resources:

Canavan Disease ResearchPhone: 800-83-2194

Canavan Foundation, Inc.Phone: 877-422-6282

Canavan Research FoundationPhone: 203-240-2326

Genetic AlliancePhone: 202-966-5557 or 800-336-4363

Genetic and Rare Diseases (GARD) Information Center

MedlinePlus

PubMed

National Tay-Sachs and Allied Diseases AssociationPhone: 617-227-4463

United Leukodystrophy FoundationPhone: 815-748-3211 or 800-728-5483

## Learn about related topics

              - Leukodystrophy 

book-open
<TABLE> <S> <C>

<ARTICLE> 5
<CIK> 0000824840
<NAME> ADVANTAGE LIFE PRODUCTS, INC.
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               SEP-30-1998
<CASH>                                               0
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                       0
<CURRENT-LIABILITIES>                        2,540,826
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       149,449
<OTHER-SE>                                 (2,690,275)
<TOTAL-LIABILITY-AND-EQUITY>                         0
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                23,704
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                               (23,704)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (23,704)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                         0
<EPS-BASIC>                                      (.03)
<EPS-DILUTED>                                    (.03)


</TABLE>
Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Ryan E. Kirch, certify that:

1.

I have reviewed this quarterly report on Form 10-Q of Brekford International Corp.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrants other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)

Intentionally Omitted;

c)

Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of end of the period covered by this report based on such evaluation; and,

d)

Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and

5.

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.



|                        |                                           
|----------------------- | ------------------------------------------
|Date:  October 31, 2008 | /s/ RYAN E. KIRCH                         
|                        | Ryan E. Kirch,
Principal Financial Officer
# Headquarters (HQ) and Extramural Staff Organizational Locator

## Office of the Director

### Office for Disparities Research and Workforce Diversity

### Office of Clinical Research

#### Clinical Trials Operations and Biostatistics Branch (HN71L3)

#### Human Research Protection Branch

#### Office of the Director

### Office of Genomics Research Coordination

### Office of National Autism Coordination

#### Office of Autism Research Coordination

### Office of Resource Management

#### Ethics Branch

#### Extramural Administrative Services Branch

#### Information Resource and Technology Management Branch

#### Office of Intramural Research Administration

##### Intramural Administrative Oversight Branch

##### Intramural Administrative Services Branch

#### Personnel Management Branch

#### Planning and Financial Management Branch

#### Workforce and Resource Management Branch

### Office of Science Policy, Planning and Communications

#### Electronic Communications Branch

#### Reports and Analysis Branch

#### Science Policy and Evaluation Branch

#### Science Writing, Press, and Dissemination Branch

## Division of Extramural Activities

### Extramural Policy Branch

### Extramural Review Branch

### Grants Management Branch

## Division of Neuroscience and Basic Behavioral Science

### Behavioral Science and Integrative Neuroscience Research Branch

### Developmental & Genomic Neuroscience Research Branch

### Genomics Research Branch

### Molecular and Cellular Neuroscience Research Branch

## Division of Translational Research

### Adult Pathophysiology and Biological Interventions Development Branch

### Adult Psychopathology and Psychosocial Interventions Development Branch

### Biomarker & Intervention Development for Childhood-Onset Mental Disorders Branch

### Developmental Mechanisms and Trajectories of Psychopathology Branch

### Geriatrics and Aging Processes Research Branch

### Office of the Director, DTR

## Division of Services and Intervention Research

### Services Research and Clinical Epidemiology Branch

### Treatment and Preventive and Intervention Research Branch 

## Division of Data Science and Technology

### Infrastructure Branch

### Technology Development Branch

## Division of AIDS Research

### Center for Global Mental Health Research

### Center for Mental Health Research on AIDS

### HIV Neuropathogenesis, Genetics, and Therapeutics Branch HN798

### HIV Prevention Science Branch

### HIV Treatment and Translational Science Branch
#### In the Matter of Jazmine Weisman et al., Appellants, v New York City Housing Authority, Respondent.

Submitted July 30, 2012;

decided September 6, 2012

*1009Motion for reargument of motion for leave to appeal denied *[see*19 NY3d 921 (2012)]. Motion for a stay dismissed as academic.
```

[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 321 Introduced in House (IH)]

<DOC>

116th CONGRESS
  1st Session
H. RES. 321

 Recognizing the historic, cultural, and religious significance of the 
             festival of Vaisakhi, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             April 15, 2019

Mr. Garamendi (for himself, Ms. Bass, Ms. Meng, Mr. Cox of California, 
  Mr. Meeks, Mr. Pallone, Ms. Judy Chu of California, and Mr. Costa) 
submitted the following resolution; which was referred to the Committee 
                        on Oversight and Reform

_______________________________________________________________________

                               RESOLUTION

 
 Recognizing the historic, cultural, and religious significance of the 
             festival of Vaisakhi, and for other purposes.

Whereas Vaisakhi has been celebrated in the Punjab region of South Asia for 
        centuries and today is also celebrated in communities throughout India, 
        in the United States, and around the world;
Whereas Vaisakhi is an annual festival celebrating the spring harvest season;
Whereas Vaisakhi is of particular significance to the Sikh religion and is one 
        of the most important dates in Sikh history;
Whereas, for Sikhs, Vaisakhi commemorates the creation of the Khalsa, a 
        fellowship of devout Sikhs, by Guru Gobind Singh in 1699; and
Whereas Vaisakhi celebrates community, prosperity, and continued progress in the 
        year ahead: Now, therefore, be it
    Resolved, That the House of Representatives--
            (1) recognizes the historic, cultural, and religious 
        significance of the festival of Vaisakhi;
            (2) recognizes the significance of Vaisakhi to Sikh 
        communities in the United States and around the world; and
            (3) expresses its respect for all communities that 
        celebrate Vaisakhi.
                                 <all>
```